Cassava, SEC and Alzheimer
SEC Charges Cassava Sciences, Former Executives for Misleading Claims in Alzheimer's Trial
Cassava Sciences and two former executives will pay more than $40 million to settle charges related to misleading statements made about a clinical trial for the company's purported therapeutic treatment of Alzheimer's disease, the Securities and Exchange Commission said on Thursday.
Discover how exercise, a healthy diet, and socialization can help combat Alzheimer's disease. Learn more about the importance ...
The Alzheimer’s Alliance of Smith County hosted its 11th annual Butterfly Luncheon to raise money and awareness of Alzheimer’s and dementia. Organizers of the event said 4,500 people are dealing with ...
A report published Wednesday in The BMJ questioned the safety and effectiveness of the Alzheimer’s disease drug Kisunla ...
The 'Shark Tank' star and real-estate icon shares how she and her 9 siblings became caregivers when their mother, Florence, ...
Subtle changes in brain activity in the presence of both amyloid-beta and tau proteins may point to Alzheimer's disease, long ...
The safety and effectiveness of donanemab—an Alzheimer's drug recently approved by the US Food & Drug Administration (FDA)—is ...
The National Institutes of Health awarded a five-year, $3.7 million grant to the Oklahoma Medical Research Foundation (OMRF) ...
Leptin, a hormone that helps with weight control, also plays a role in normal cognition. Leptin resistance occurs when the ...
The Connecticut State Department of Health forecasts the number of Connecticut residents living with Alzheimer’s to grow to ...
A startling investigation has revealed a troubling story behind donanemab's approval -- one of questionable data, potential ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback